Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04637334 · ClinicalTrials.gov registry record
Superior Vena Cava Reconstruction in Patients on Hemodialysis
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 45
- Enrollment target
NCT04637334: Completed study, sponsored by Methodist Health System.
NCT04637334 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04637334 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
The treatment objective for patients with SVC syndrome secondary to both malignant and benign etiologies is to reduce the elevated central venous pressures.1 However, the strategies are contingent upon the underlying disease process. Thus the management of SVC syndrome ranges from medical or supportive care to surgical bypass,3 and it is important for physicians to understand the varied treatment modalities of this potentially life-threatening disease.17 Fortunately, the overwhelming majority of patients with SVC syndrome secondary to benign causes develop a physiologic compensation for the obstruction that can be treated with anticoagulation and endovascular modalities. Intervention for symptomatic relief may not be required.1 An endovascular approach is the current standard of care to relieve SVC obstruction due to malignancy to obtain prompt relief of the rapidly emerging symptoms and improve quality of life,3 keeping in mind the short life expectancy of these patients. The role of endovascular therapy in SVC syndrome of nonmalignant etiology is undecided because the long-term durability of this treatment method remains to be assessed.
Primary Outcome
To report findings in patients with ESRD on hemodialysis who underwent SVC reconstruction
Interventions
- PROCEDURE Superior vena cava reconstruction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-09-13 |
| Est. Completion | 2022-05-06 |
What the finished NCT04637334 record still lists
NCT04637334 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Superior vena cava reconstruction is the first listed.
NCT04637334 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04637334 about?
NCT04637334 is a clinical study titled "Superior Vena Cava Reconstruction in Patients on Hemodialysis". The treatment objective for patients with SVC syndrome secondary to both malignant and benign etiologies is to reduce the elevated central venous pressures.1 However, the strategies are contingent upon the underlying disease process. Thus the management of SVC syndrome ranges from medical or support...
What is the current status of trial NCT04637334?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2014-09-13. Estimated completion is 2022-05-06.
What interventions are being tested in trial NCT04637334?
The interventions under investigation include: Superior vena cava reconstruction (PROCEDURE).
Who is sponsoring clinical trial NCT04637334?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI